Mike Desjadon has a pointed way of describing the relationship between hospitals and insurance companies: "Payers deploy seven or more payment integrity vendors to contest provider claims." It's an arms race, he says, and for years the hospitals have been outgunned.
Now his company, Anomaly, wants to shift the balance. The New York-based startup announced in May 2026 that it has closed $17 million in fresh funding to expand an AI platform designed to help health systems predict—and prevent—claim denials before they happen. Sound Ventures led the round, with Alumni Ventures joining alongside earlier investors Link Ventures, Redesign Health, and RRE Ventures. The raise brings Anomaly's total capital to $34 million since its launch in 2020.
What sets Anomaly apart, at least in theory, is the timing. Most revenue cycle tools help hospitals fight denials after the fact, a laborious and expensive process. Anomaly's Smart Response platform attempts to reverse-engineer the logic insurers use to reject claims, then flags potential problems before a bill ever leaves the system. Think of it as moving from defense to offense—or at least trying to.
"Health systems have operated at an information disadvantage for too long," said Juliette Bolea, an investor at Sound Ventures who joined Anomaly's board as part of the deal. She's not wrong. The American Hospital Association estimated earlier this year that U.S. hospitals collectively burn through $43 billion annually chasing down payments tied up in denials and prior authorization disputes. Separately, the Kaiser Family Foundation found that roughly one in five claims submitted to ACA marketplace plans were denied outright.
That's the market opportunity Anomaly is chasing. The company says it's now embedded in more than 20 health systems, where it has recovered tens of millions in contested revenue—though it hasn't broken out specific figures by customer. Bronson Healthcare, one of its clients, highlighted the platform's integration with Epic, the ubiquitous electronic health record system. The appeal there is straightforward: staff don't need to learn yet another interface. Smart Response sits inside the workflow they're already using.
Anomaly's pitch rests on what Desjadon calls a "Predict, Detect, Recover" model. The company has reported that its engine achieved better than 97% precision in identifying actionable denials—a benchmark that, if accurate, would put it ahead of many legacy tools in the space. The company hasn't released updated performance metrics recently, though that's not uncommon for startups reluctant to show their hand to competitors.
Still, precision is only part of the story. Accuracy in prediction matters less if hospitals lack the capacity to act on the insights, or if payers simply change the rules. And they do change the rules—frequently. That's why Anomaly is using the new capital to push beyond post-payment recovery into murkier terrain: managed care operations and contract negotiations.
This is where things get more complex. Payer behavior during contract talks has historically been opaque, a black box that leaves hospital CFOs guessing at reimbursement rates and coverage terms. Anomaly believes it can crack that open by surfacing patterns in how insurers negotiate and enforce contracts. Whether health systems will pay for that intelligence—and whether it actually moves the needle in high-stakes negotiations—remains to be seen.
The company plans to scale its workforce as it broadens its product footprint, though it hasn't disclosed current headcount or hiring targets. That vagueness is typical for early-stage companies wary of tipping off rivals or locking themselves into public commitments.
What's clear is that Anomaly is making a broader bet: that hospitals need visibility into payer behavior across the entire revenue cycle, not just at the claims stage. If denials are a symptom of deeper information asymmetry—and Desjadon argues they are—then solving the problem means going upstream, into the moments where contracts are written and coverage decisions are made.
Whether that bet pays off will depend on execution, and on whether health systems, already stretched thin, see enough value to integrate yet another layer of tooling into their operations. For now, Anomaly has the capital to find out.
